Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Can hepatitis C virus core antigen replace quantitative RNA in the assessment of a sustained virologic response?

The Egyptian Journal of Internal Medicine volume 31, pages 529–535 (2019)Cite this article

Abstract

Background

The widespread use of direct-acting antivirals (DAAs) in the treatment of hepatitis C virus (HCV) infection has reduced the need for monitoring HCV-RNA levels because viral kinetics do not predict a sustained virologic response (SVR). However, the performance of cheaper tests, such as the assay to quantify hepatitis C virus core antigen (HCV Ag), has not been determined. Our aim was to assess the accuracy of the HCV core Ag test in predicting the achievement of SVR and its predictive value as a monitoring test in the course of treatment.

Patients and methods

This prospective study was carried out on 90 patients, chronically infected with HCV, who received DAA therapy. Blood samples were collected and the levels of HCV core Ag and HCV-RNA were measured at baseline and at 12 weeks after the end of treatment. We compared the ability of these assays to predict which patients would achieve SVR12.

Results

The baseline level of HCV-RNA was 1 688 529.6±994 697.3 IU/ml (range: 312 700–3 491 100 IU/ml) and HCV core Ag was 179.2±83.5 pg/ml (range: 33.5–315.6 pg/ml). HCV Ag became undetectable in 92.2% 12 weeks after the end of treatment, whereas HCV-RNA became undetectable in 87.8% at the end of treatment (P<0001). Seventy-nine out of 90 (87.8%) patients achieved SVR12; the test for HCV Ag identified 63.6% of these patients.

Conclusion

Measurement of HCV core Ag can monitor the efficacy of DAA therapy for HCV infection. Thus, it can be applied in clinical practice.

References

  1. Cooke GS, Lemoine M, Thursz M, Gore C, Swan T, Kamarulzaman A, et al. Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat 2013; 20:600–601.

    Article  CAS  Google Scholar 

  2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333–1342.

    Article  Google Scholar 

  3. Gower EEC, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45–S57.

    Article  Google Scholar 

  4. World Health Organization. Hepatitis C Fact Sheet. 2015.

  5. Ward JW, Mermin JH. Simple, effective, but out of reach? Public Health Implications of HCV Drugs. N Engl J Med 2015; 373:2678–2680.

    PubMed  Google Scholar 

  6. Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, et al. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One 2014; 9:e97317.

    Article  Google Scholar 

  7. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8:280–288.

    Article  Google Scholar 

  8. Pockros PJ. Management of patients who have achieved sustained virologic response for hepatitis C virus infection. Gastroenterol Hepatol (N Y) 2018; 14:305–307.

    Google Scholar 

  9. Morisco F, Loperto I, Stroffolini T, Lombardo FL, Cossiga V, Guarino M, et al. Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: tail of a cohort infected in past decades. J Med Virol 2016; 89:291–297.

    Article  Google Scholar 

  10. Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, et al. International survey on NAT testing of blood donations: expanding implementation and yield from1999 to 2009. Vox Sang 2012; 102:82–90.

    Article  CAS  Google Scholar 

  11. Florea D, Neaga E, Nicolae I, Maxim D, Popa M, Otelea D. Clinical usefulness of HCV core antigen assay for the management of patients with chronic hepatitis C. J Gastrointestin Liver Dis 2014; 23:393–396.

    Article  Google Scholar 

  12. Alonso R, Perez-Garcia F, Ampuero D, Reigadas E, Bouza E. New direct-acting antivirals for patients with chronic HCV infection: can we monitor treatment using an HCV core antigen assay? Diagn Microbiol Infect Dis 2017; 87:243–246.

    Article  CAS  Google Scholar 

  13. Mixson-Hayden T, Dawson GJ, Teshale E, Le T, Cheng K, Drobeniuc J, et al. performance of architect HCV core antigen test with specimens from US plasma donors and injecting drug users. J Clin Virol 2015; 66:15–18.

    Article  Google Scholar 

  14. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26:401–412.

    Article  Google Scholar 

  15. The Global Burden of Hepatitis C. The global burden of hepatitis C. J Clin Pharmacol 2004; 44:20–29.

    Article  Google Scholar 

  16. Poiteau L, Soulier A, Rosa I, Roudot-Thoraval F, Hézode C, Pawlotsky JM, et al. Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots. J Viral Hepat. 2016; 23(5):399–401.

    Article  CAS  Google Scholar 

  17. Bouvier-Alias M, Keyur P, Harel D, Stephanie B, Patrick L, Lawrence B, et al. clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002; 36:212–215.

    Article  Google Scholar 

  18. Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, et al. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Clin Microbiol 1999; 37:1802–1808.

    Article  CAS  Google Scholar 

  19. Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H, et al. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods 2009; 157:8–14.

    Article  CAS  Google Scholar 

  20. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005; 45:994–1002.

    Article  Google Scholar 

  21. Medici MC, Furlini G, Rodella A, Fuertes A, Monachetti A, Calderaro A, et al. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol 2011; 51:264–269.

    Article  Google Scholar 

  22. Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 2015; 59:1505–1511.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Khalifa El-Maamon St., Abbassia, Cairo, 11341, Egypt

    Nevine I. Musa MD, Eslam Safwat & Ramy S. Ghait

  2. Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Heba Aly

  3. Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Dalia H. Abdelhamid

Authors
  1. Nevine I. Musa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eslam Safwat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ramy S. Ghait
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Heba Aly
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dalia H. Abdelhamid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nevine I. Musa MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Musa, N.I., Safwat, E., Ghait, R.S. et al. Can hepatitis C virus core antigen replace quantitative RNA in the assessment of a sustained virologic response?. Egypt J Intern Med 31, 529–535 (2019). https://doi.org/10.4103/ejim.ejim_88_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_88_19

Keywords